BioSpace News Archive

Rocket Lab now operates the world’s largest production line of high-performing space solar cells.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody.

Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to provide Parse’s Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits and Nuclei Fixation Kits to markets in Singapore and Southeast Asia.

The Bill & Melinda Gates Foundation and Wellcome each pledged US$150 million for a total of US$300 million to the Coalition for Epidemic Preparedness Innovations, a global partnership launched five years ago this week by the governments of Norway and India, the Gates Foundation, Wellcome, and the World Economic Forum.

The clinical gadget contract fabricating market is relied upon to show extensive development because of variables, for example, expanding medical problems and the requirement for appropriate determination.

Advances in ureteroscopic innovation, close by widening treatment choices have fuelled the fast development of endourology.

Fact.MR – A Market Research and Competitive Intelligence Provider: The ultra-low temperature freezer market to register steady growth for the forecast period.

Biochemical reagents are extensively used in range of applications in the life sciences industry, including in research.

Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.

More than one billion people worldwide suffer from anemia of inflammation or anemia of chronic diseases (ACD) – and for the first time we may know why. New research from The Feinstein Institutes for Medical Research, published in Blood, shows that high mobility group box-1 protein (HMGB1) prevents the body’s ability to produce sufficient levels of oxygen-rich red blood cells.